China's President Xi Jinping met with global CEOs in Beijing on Friday, as the government tries to woo foreign firms whose ...

China's President Xi Jinping urged a gathering of global CEOs on Friday to protect industrial and supply chains, as Beijing ...

The latest data from Johnson and Johnson's Rybrevant and Lazcluze lung cancer combo was better than standard of care Tagrisso ...

The World Business Council for Sustainable Development (WBCSD), in collaboration with leading pharmaceutical companies and ...

One half of J&J’s treatment is Lazcluze, a pill that, like Astra’s Tagrisso, blocks a cancer-associated protein called EGFR.

U-M researchers at the Rogel Cancer Center, in collaboration with Arcascope, have developed and tested a personalized app that tracks a user’s circadian rhythm and makes behavioral recommendations to ...

1. AstraZeneca to invest $2.5 billion in new global strategic R&D centre, biotech agreements and manufacturing in Beijing.

Johnson & Johnson has produced the most convincing data to date that its combination of Rybrevant and Lazcluze could replace ...

CINCINNATI ( Cincinnati Business Courier) - A growing biotech and pharmaceuticals manufacturer that announced a large ...

AstraZeneca Plc‘s win over shareholders who challenged its $3 billion sale of biotech firm Viela Bio Inc. was affirmed Wednesday by the Delaware Supreme Court.

New study results presented at the European Lung Cancer Congress 2025, March 26 to 29, demonstrate the role of AstraZeneca’s (AZN) TAGRISSO, as ...